WO1998030717A2 - Vegetal sequences including a polymorphic site and their uses - Google Patents
Vegetal sequences including a polymorphic site and their uses Download PDFInfo
- Publication number
- WO1998030717A2 WO1998030717A2 PCT/EP1997/007134 EP9707134W WO9830717A2 WO 1998030717 A2 WO1998030717 A2 WO 1998030717A2 EP 9707134 W EP9707134 W EP 9707134W WO 9830717 A2 WO9830717 A2 WO 9830717A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- allele
- sequence
- specific oligonucleotide
- segment
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 40
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 38
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 38
- 239000002773 nucleotide Substances 0.000 claims abstract description 24
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 23
- 230000000295 complement effect Effects 0.000 claims abstract description 8
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 108700028369 Alleles Proteins 0.000 claims description 39
- 108091034117 Oligonucleotide Proteins 0.000 claims description 25
- 239000000523 sample Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 230000037353 metabolic pathway Effects 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 229920005610 lignin Polymers 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000003976 plant breeding Methods 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 24
- 239000000047 product Substances 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 230000003321 amplification Effects 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 240000008042 Zea mays Species 0.000 description 10
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 10
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 9
- 235000009973 maize Nutrition 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000001938 protoplast Anatomy 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 101100015323 Caenorhabditis elegans bre-1 gene Proteins 0.000 description 4
- 108091092878 Microsatellite Proteins 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 101150094969 rfp1 gene Proteins 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 101150078509 ADH2 gene Proteins 0.000 description 3
- 101150026777 ADH5 gene Proteins 0.000 description 3
- 208000035240 Disease Resistance Diseases 0.000 description 3
- 101100269269 Drosophila mayaguana Adh gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108020005196 Mitochondrial DNA Proteins 0.000 description 3
- 101100054943 Mus musculus Adh4 gene Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- -1 nucleoside triphosphates Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 102220283790 rs1555932413 Human genes 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 241000023308 Acca Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102220499010 Ankyrin repeat domain-containing protein 33B_S71R_mutation Human genes 0.000 description 1
- 101100160805 Bacillus subtilis (strain 168) yxaF gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 102220589537 Catenin beta-1_S23R_mutation Human genes 0.000 description 1
- 102220589655 Catenin beta-1_S29F_mutation Human genes 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101710203190 Mid1-interacting protein 1 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102220537312 Protein NDRG2_S33R_mutation Human genes 0.000 description 1
- 102220537305 Protein NDRG2_S34R_mutation Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 102220484140 T cell receptor alpha variable 34_S63R_mutation Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102220544599 Tyrosinase_S44R_mutation Human genes 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 102220363628 c.200C>T Human genes 0.000 description 1
- 102220363661 c.36C>A Human genes 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102220332718 rs1008906897 Human genes 0.000 description 1
- 102200046175 rs104894187 Human genes 0.000 description 1
- 102200086354 rs104894625 Human genes 0.000 description 1
- 102200148733 rs116840794 Human genes 0.000 description 1
- 102200044935 rs121913400 Human genes 0.000 description 1
- 102200044886 rs121913409 Human genes 0.000 description 1
- 102200081489 rs121913585 Human genes 0.000 description 1
- 102200081496 rs121913598 Human genes 0.000 description 1
- 102220004804 rs121917719 Human genes 0.000 description 1
- 102200041248 rs1233331806 Human genes 0.000 description 1
- 102220295302 rs1296837467 Human genes 0.000 description 1
- 102220263973 rs1323126988 Human genes 0.000 description 1
- 102220324591 rs1365453773 Human genes 0.000 description 1
- 102220283965 rs1426424086 Human genes 0.000 description 1
- 102200128606 rs143456784 Human genes 0.000 description 1
- 102220289826 rs1555407420 Human genes 0.000 description 1
- 102200149451 rs1800361 Human genes 0.000 description 1
- 102220008761 rs193922218 Human genes 0.000 description 1
- 102200004177 rs199473446 Human genes 0.000 description 1
- 102220024392 rs267607495 Human genes 0.000 description 1
- 102200068708 rs281865216 Human genes 0.000 description 1
- 102200158802 rs34017450 Human genes 0.000 description 1
- 102200092683 rs371769427 Human genes 0.000 description 1
- 102220039007 rs3743601 Human genes 0.000 description 1
- 102220072404 rs541043583 Human genes 0.000 description 1
- 102220033063 rs61755766 Human genes 0.000 description 1
- 102220058400 rs730881695 Human genes 0.000 description 1
- 102220067485 rs759094089 Human genes 0.000 description 1
- 102220242537 rs762217448 Human genes 0.000 description 1
- 102220211940 rs76429508 Human genes 0.000 description 1
- 102200038213 rs767568897 Human genes 0.000 description 1
- 102200110148 rs768071555 Human genes 0.000 description 1
- 102220092171 rs770694213 Human genes 0.000 description 1
- 102220463950 rs7782939 Human genes 0.000 description 1
- 102220081547 rs863223734 Human genes 0.000 description 1
- 102220083081 rs863224628 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form or may be neutral.
- a variant form confers a lethal disadvantage and is not transmitted to subsequent generations of the organism.
- a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form.
- both progenitor and variant form(s) survive and co-exist in a species population. The coexistence of multiple forms of a sequence gives rise to polymorphisms.
- a restriction fragment length polymorphism means a variation in DNA sequence that alters the length of a restriction fragment as described in Botstein et al., Am. J. Hum . Genet . 32, 314-331 (1980).
- the restriction fragment length polymorphism may create or delete a restriction site, thus changing the length of the restriction fragment.
- RFLPs have been widely used in human and animal genetic analyses (see WO 90/13668; WO 90/11369; Donis-Keller, Cell 51, 319-337 (1987); Lander et al . , Genetics 121, 85-99 (1989)).
- a heritable trait can be linked to a particular RFLP, the presence of the RFLP in an individual can be used to predict the likelihood that the animal will also exhibit the trait.
- VNTR variable number tandem repeat
- Such polymorphisms are far more frequent than RFLPs, STRs and VNTRs .
- Some single nucleotide polymorphisms occur in proteincoding sequences, in which case, one of the polymorphic forms may give rise to the expression of a defective or other variant protein.
- Other single nucleotide polymorphisms occur in noncoding regions . Some of these polymorphisms may also result in defective or variant protein expression (e.g., as a result of defective splicing) .
- Other single nucleotide polymorphisms have no phenotypic effects .
- Single nucleotide polymorphisms can be used in the same manner as RFLPs, and VNTRs but offer several advantages .
- Single nucleotide polymorphisms occur with greater frequency and are spaced more uniformly throughout the genome than other forms of polymorphism.
- the greater frequency and uniformity of single nucleotide polymorphisms means that there is a greater probability that such a polymorphism will be found in close proximity to a genetic locus of interest than would be the case for other polymorphisms.
- the different forms of characterised single nucleotide polymorphisms are often easier to distinguish that other types of polymorphism (e.g., by use of assays employing allele-specific hybridization probes or primers) .
- the invention provides nucleic acid segments containing at least 10, 15 or 20 contiguous bases from a vegetal fragment including a polymorphic site notably a single nucleotide polymorphism (SNP).
- a vegetal fragment does not belong to the Cruciferae family .
- the segments can be DNA or RNA, and can be double- or single-stranded. Some segments are 10-20 or 10-50 bases long. Preferred segments include a diallelic polymorphic site.
- the invention concerns nucleic acid segments from a fragment shown in Table I (corn) .
- the Invention further provides allele-specific oligonucleotides that hybridizes to a segment of a vegetal fragment, for example fragment in Table I. These oligonucleotides can be probes or primers .
- isolated nucleic acid comprising a sequence of Table I or the complement thereto, in which the polymorphic site within the sequence is occupied by a base other than the reference base shown in Table I .
- the invention further provides a method of analyzing a nucleic acid from a subject.
- the method determines which base or bases is/are present at any one of the polymorphic vegetal sites for example of those of Table I.
- a set of bases occupying a set of the polymorphic sites shown in Table I is determined. This type of analysis can be performed on a plurality of subjects who are tested for the presence of a phenotype. The presence or absence of phenotype can then be correlated with a base or set of bases present at the polymorphic sites in the subjects tested.
- a nucleic acid such an oligonucleotide
- oligonucleotide can be DNA or RNA, and single- or double-stranded.
- Oligonucleotides can be naturally occurring or synthetic, but are typically prepared by synthetic means.
- Preferred nucleic acids of the invention include segments of DNA, or their complements including any one of the polymorphic sites shown in Table I. The segments are usually between 5 and 100 bases, and often between 5-10, 5-20, 10-20, 10-50, 20-50 or 20-100 bases. The polymorphic site can occur within any position of the segment. The segments can be from any of the allelic forms of DNA shown in Table I. Methods of synthesizing oligonucleotides are found in, for example, Oligonucleotide Synthesis : A Practical ApproacA (Gait, ed., IRL Press, Oxford, 1984).
- Hybridization probes are oligonucleotides capable of binding in a base-specific manner to a complementary strand of nucleic acid. Such probes include peptide nucleic acids, as described in Nielsen et al . , Science 254, 1497-1500 (1991) .
- primer refers to a single-stranded oligonucleotide capable of acting as a point of initiation of template-directed DNA synthesis under appropriate conditions (i.e., in the presence of four different nucleoside triphosphates and an agent for polymerization, such as, DNA or RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature.
- the appropriate length of a primer depends on the intended use of the primer but typically ranges from 15 to 30 nucleotides . Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template
- a primer need not reflect the exact sequence of the template but must be sufficiently complementary to hybridize with a template.
- primer site refers to the area of the target DNA to which a primer hybridizes .
- primer pair means a set of primers including a 5 ' upstream primer that hybridizes with the 5 ' end of the DNA sequence to be amplified and a 3 ' , downstream primer that hybridizes with the complement of the 3 ' end of the sequence to be amplified.
- Linkage describes the tendency of genes, alleles, loci or genetic markers to be inherited together as a result of their location on the same chromosome, and can be measured by percent recombination between the two genes, alleles, loci or genetic markers.
- Polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population.
- a polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population.
- a polymorphic locus may be a" small as one base pair.
- Polymorphic markers include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, minisatelli tes , dinucleotide repeats, trinucleotide repeats, tetranucleotide repeats, simple sequence repeats, and insertion elements such as Alu .
- allelic form is arbitrarily designated as a the reference form and other allelic forms are designated as alternative or variant alleles.
- allelic form occurring most frequently in a selected population is sometimes referred to as the wildtype form. Diploid organisms may be homozygous or heterozygous for allelic forms.
- a diallelic polymorphism has two forms.
- a triallelic polymorphism has three forms.
- a single nucleotide polymorphism occurs at a polymorphic site occupied by a single nucleotide, which is the site of variation between allelic sequences. The site is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in 1QSS than 1/100 or 1/1000 members of the populations) .
- a single nucleotide polymorphism usually arises due to substitution of one nucleotide for another at the polymorphic site.
- a transition is the replacement of one purine by another purine or one pyrimidine by another pyrimidine.
- a transversion is the replacement of a purine by a pyrimidine or vice versa.
- Single nucleotide polymorphisms can also arise from a deletion of a nucleotide or an insertion of a nucleotide relative to a reference allele.
- Hybridizations are usually performed under stringent conditions, for example, at a salt concentration of no more than 1 M and a temperature of at least 25°C
- conditions of 5X SSPE 750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4 and a temperature of 25-30°C are suitable for allele-specific probe hybridizations.
- Nucleic acids of the invention are often in isolated form.
- An isolated nucleic acid means an object species that is the predominant species present (i.B., on a molar basis it is more abundant than any other individual species in the composition) .
- an isolated nucleic acid comprises at least about 50, 80 or 90 percent (on a molar basis) of all macromolecular species present.
- the object species is purified to essential homogeneity (contaminant specie" cannot be detected in the composition by conventional detection methods) .
- Novel Polymorphisms of the Invention provides for example oligonucleotides containing polymorphic sequences isolated from graminae species for example maize.
- the invention also includes various methods for using those novel oligonucleotides to identify, distinguish, and determine the relatedness of individual strains or pools of nucleic acids from plants .
- DNA was extracted from maize lines as described in Rogers and Bendich (1988 Plant Mol Biol Manual A6 : 1- 10) with modification described in Murigneux et al (1993 theo Appl Genet 86 : 837-842) .
- PCR amplification was done on six maize lines representing a wide range of genetic variability and including both European flint material and US dent germplasm. Those six maize lines have been choosen to maximize the genetic variability of cultivated maize. Doing so, optimize the chance of finding polymorphism in the allelic sequences. For example Gl, an european flint line and G3 , an US Corn Belt Stiff Stalk line, are completly unrelated. Their genetic distance (coefficient of dissimilarity) calculated with our standard approach (89 RFLP probe/enzyme combinations and Nei-li distance) is 0.69. This value is close to the maximum distance between two cultivated maize lines .
- Genotypes Among the 15 genetic distance between couple of these 6 lines : 8 are superior to 0.6, 6 superior to 0.5 and only one inferior to 0.5. This shows that the choice of the lines avoided as much as it was possible the potential redudancy (or similarity) of allele at the locus sequenced. With the same effort of sequencing we should therefore have collected the maximum number of polyphomism. Genotypes :
- the markers have been chosen with the following criteria.
- MAP Pos map position, given by the bin location of the
- 5.01 means that it is located in the bin 5.01 (on chromosome
- S01R is the reverse primer for probe 1
- Genbank/ EMBL Genbank/ EMBL number TABLE A
- Adh2 S17 4.03 S17F2 TGCCTGCTGCATCTCTAGCC X02915 S17R2 CAAGCCCGAAAATCGCCAC X02915
- PCR amplification was done with primer designed using the DNA sequences of the markers listed above.
- the sequences for all markers/genes were available on Genbank/ EMBL.
- Polymerisation was done in a perkin Elmer 9600 : 1' at 95°C, followed by 35 cycles of (30" at 94°C, 30" at 60°C, 1'30" at 72°C) followed by 1'30" at 72°C.
- Column 1 (Bt2) represents the name of the marker or gene .
- SNP single nucleotide polymorphism
- Column 3 represents : similar to column 2, but with the codification of the marker/gene.
- /G CSU61-G1/G5-1A means deletion of the base pair G in Gl compared to G5.
- ASG12 ASG12-G1/G3-1 S6 G1/G3-1 CTGGTRGAAATGTGTTGAAG[CA]TACTAGTGATGAACTGCTTG
- ASG12 ASG12-G1/g3-3B S6 G1/g3-3B CGCGCCGAAAAAGGAAAAAG[G ⁇ TGAAGGTCCT ⁇ ACTCACCGA
- Sh2 Sh2-G3 G6-1 S63G3G6-1 TCTGTGATTGGAGTCTGCTC[G/A]CGTGTCAGCTCTGGATGTGA
- CSU61 CSU61-G5A36-2B S 5G5 ⁇ 36-2B CCTAAACGCTGACCGCCACAIGAJACGGCGGCGGCTGCCAAATC
- Wx1 Wx1-G2/G6-2B S43G2/G6-2B CTTGATTGCATTGCAGCTAC[A G]AGAAGCCCGTGGAAGGCCGG
- Wx1 WX1-G6/G1-1 S43G6K31-1 CTCCTACCAGGGCCGGTTCG ⁇ T/ICCTTCTCCGACTACCCGGAG
- UMC80 UMC80-G2 ⁇ 33-1 S34G2 G3-1 GAGACAT ⁇ C «TACTCV ⁇ TA( ⁇ AA ⁇ ATTTGATGAAATTATT
- ASG 9 ASG49-G3/G5-2 S32G3 G5-2 ATGAATTGAAGCTCTGAATA[(VnAGAATCCACCATTCTTCCGA
- ASG 9 ASG49-G3/G5-3 S32G3 G5-3 GAATCCACCATTCTTCCGAAIA GICTGCTTCCTACAAAACTCGA
- ASG8 ASG8-G3 G4-1 S31G3 G4-1 TGTATCGGCTAGTCTGGATG[G/AJTCGCACTGGCACTCAGTGCT csnpld
- U C 2 1 UMC21-G5/G6-1 S 2 8G5/G6-1 CAAGAAGCCTCTTCAGTGTC[A C]GTCGTAGCTTCCTCAAGACC
- UMC21 UMC21-G5/G6-3 S28G5/G6-3 CTAATCCATGGAGCAGGGAG[G A]AAGGGGCGAGGGGCAGCAAG
- Ae1 Ae1-G1/G6-1 S23G1/G6-1 TGATTCGGGTCTGTATGCGAtG T GTTGTGGTGGTGAACTGGT
- Ae1 Ae1-G1/G4-1 S23G1/G4-1 GTTCGCGGTTTCTGGGGCCG[G ⁇ GGGCGGTGCTCGGTGGGGCC
- UMC90 UMC90-G5 ⁇ 36-1 S22G5/G6-1 CAGA ⁇ GGTGTCGT ⁇ rACTAIA/GJAATTCAGTTCTGTCCATTTG
- ASG24 ASG24-G5 G6-1 S13G5/G6-1 TTTCACAACTCAACTGATTGIANTCTTGCTTTGATGTGGATTCT
- UMC131 UMC131-G4/G6-1 S10G4 G6-1 AGCGACAGGGATGTCGAGCA[G TTCTACGGAAGGCAATAATGAG csnpld
- UMC131 UMC131-G3G6-1 S10G3G6-1 GCATGGCGGAGTGAGGGAGG(TG/]TGTGTGTGTGGCTCCACA
- UMC131 UMC131-G3/G6-2B S10G3G6-2B GGCCGCTACGCCATTTAGCG[G/A1ATTTGGGAAAATCAATGCAC
- UMC53 UMC53-G4G6-1 UMC53-G4G6-1 GCAGCCTCAGGTACACGGGG[/A]AAGTCGGAGTGGTTCTTCAC
- UMC161 UMC161-G2G3-2 S06G2G3-2 ACGGTGAGGAGTGGCACATG[AC]GATGGAAAGTTCCTGTAGAC
- UMC76 UMC76-G2G5-1B S02G2G5-1B TAGTTTCTCGGCAATTGGCAfG ⁇ TGTGGAATGACCATCTCGTC
- UMC76 UMC76-G2/G5-2B S02G2G5-2B GTGTGGAATGACCATCTCGT[G/C]GTGATGCCAGCATGCTACTA
- Target nucleic acids can be genomic or cDNA.
- Many of the methods described below require amplification of DNA from target samples. This can be accomplished by e.g., PCR. See generally PCR Technology :
- LCR ligase chain reaction
- NASBA nucleic acid based sequence amplification
- the latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dSDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.
- ssRNA single stranded RNA
- dSDNA double stranded DNA
- A Detection of Polymorphisms in Target DNA
- the first type of analysis is sometimes referred to as de novo characterization. This analysis compares target sequences in different individual plants to identify points of variation, i.e., polymorphic sites.
- de novo identification of the polymorphisms of the invention is described in the Examples section.
- the second type of analysis is determining which form(s) of a characterized polymorphism is (are) present in plants under test. There are a variety of suitable procedures, which are discussed in turn.
- Allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al . , Nature 324, 163-166 (1986); Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a segment of target DNA from one member of a species but do not hybridize to the corresponding segment from another member due to the presence of different polymorphic forms in the respective segments from the two members . Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles.
- Some probes are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15 mer at the 7 position; in a 16 mer, at either the 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.
- Allele-specific probes are often used in pairs, one member of a pair showing a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence .
- the polymorphisms can also be identified by hybridization to nucleic acid arrays, some example of which are described by Wo 95/11995 (incorporated by reference in its entirety for all purposes) .
- One form of such arrays is described in the Examples section in connection with de novo identification of polymorphisms.
- the same array or a different array can be used for analysis of characterized polymorphisms.
- WO 95/11995 also describes subarrays that are optimized for detection of a variant forms of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence.
- the second group of probes is designed by the same principles as described in the Examples except that the probe" exhibit complementarity to the second reference sequence.
- the inclusion of a second group (or further groups) can be particular useful for analysing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (i.e., two or more mutations within 9 to 21 bases) .
- An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, Nucleic Acid Res . 1 7 , 2427-2448 (1989) .
- This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification proceeds from the two primers leading to a detectable product signifying the particular allelic form is present.
- a control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed.
- the direct analysis of the sequence of polymorphisms of the present invention can bo accomplished using either the dideoxy chain termination method or the Maxam Gilbert method (see Sambrook et al . , Molecular Cloning, A Laboratory Manual (2nd Ed., CSHP, New York 1989); Zyskind et al . , Recombinant DNA Labora tory Manual , (Acad. Press, 1988) ) .
- Denaturing Gradient Gel Electrophoresis Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution, Erlich, ed., PCR Technology, Principles and Applications for DNA Amplification, (W. H. Freeman and Co, New York, 1992), Chapter 7.
- Alleles of target sequences can be differantiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita et al . , Proc, Nat . Acad . Sci . 86, 2766-2770 (1989) .
- Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products.
- Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence.
- the different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence difference between alleles of target sequences.
- Example 5 Methods of Use After determining polymorphic form(s) present in a subject plant at one or more polymorphic sites, this information can be used in a number of methods .
- a genetic fingerprint for an individual strain can be made by determining the nucleic acid sequence possessed by that individual strain that corresponds to a region of the genome known to contain polymorphisms. For a discussion of genetic fingerprinting in the animal kingdom, see, for example, Stokening et.al., Am. J. Hum . Genet . 48:370-382 (1991). The probability that one or more polymorphisms in an individual strain is the same as that in any other individual strain decreases as the number of polymorphic sites is increased.
- the comparison of the nucleic acid sequences from two strains at one or multiple polymorphic sites can also demonstrate common or disparate ancestry. Since the polymorphic sites are within a large region in the genome, the probability of recombination between these polymorphic sites is low. That low probability means the haplotype (the set of all the disclosed polymorphic sites) set forth in this application should be inherited without change for at least several generations.
- Knowledge of plant strain or ancestry is useful, for example, in a plant breeding program or in tracing progeny of a proprietary plant.
- Fingerprints are also used to identify an individual strain and to distinguish or determine the relatedness of one individual strain to another. Genetic fingerprinting can also be useful in hybrid certification, the certification of seed lots, and the assertion of plant breeders rights under the laws of various countries .
- polymorphisms of the invention may contribute to the phenotype of a plant in different ways. Some polymorphisms occur within a protein coding sequence and contribute to phenotype by affecting protein structure. The effect may be neutral, beneficial or detrimental, or both beneficial and detrimental, depending on the circumstances. Other polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on replication, transcription, and translation. A single polymorphism may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by polymorphisms in different genes.
- polymorphisms predispose a plant to a distinct mutation that is causally related to a certain phenotype .
- Phenotypic traits include characteristics such as growth rate, crop yield, crop quality, resistance to pathogens, herbicides, and other toxins, nutrient requirements, resistance to high temperature, freezing, drought, requirements for light and soil type, aesthetics, and height.
- Other phenotypic traits include susceptibility or resistance to diseases, such as plant cancers. Often polymorphisms occurring within the same gene correlate with the same phenotype.
- Correlation is performed for a population of plants, which have been tested for the presence or absence of a phenotypic trait of interest and for polymorphic markers sets.
- a set of polymorphisms i.e. a polymorphic set
- the alleles of each polymorphism of the set are then reviewed to determine whether the presence or absence of a particular allele is associated with the trait of interest.
- Correlation can be performed by standard statistical methods such as a K-squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted.
- Yijk n ⁇ + YSi + Pj; + X k ⁇ 13 ⁇ + ... ⁇ 17 + PE Struktur + a n +e p
- Yij k pn is the milk, fat, fat percentage, SNF , SNF percentage, energy concentration, or lactation energy record
- ⁇ is an overall mean
- YSi is the effect common to all cows calving in year-season
- X ⁇ is the effect common to cows in either the high or average selection line
- ⁇ i to ⁇ are the binomial regressions of production record on mtDNA D-loop sequence polymorphisms
- PE n is permanent environmental effect common to all records of cow n
- a n is effect of animal n and is composed of the additive genetic contribution of sire and dam breeding values and a Mendelian sampling effect
- e p is a random residual. It was found that eleven of seventeen polymorphisms tested influenced at least one production trait. Bovines having the best polymorphic forms
- a DNA pool is constructed from plants of a segregating population that are resistant and another pool is constructed from plants that are sensitive to the disease.
- Those two DNA pools are identical except for the DNA sequences at the resistance gene locus and in the surrounding genomic area. Hybridization of such DNA pools to the DNA sequences listed in Table 1 allows the simultaneous testing of several hundreds of loci for polymorphisms . Allelic polymorphism-detecting sequences that show differences in hybridization patterns between such DNA pools will represent loci linked to the disease resistance gene .
- nucleic acid pools are constructed from several individuals of a large population.
- the nucleic acid pools are hybridized to nucleic acids having the polymorphism-detecting sequences listed in Table I.
- the detection of a rare hybridization profile will indicate the presence of a rare allele in a specific nucleic acid pool.
- RNA pools are particularly suited to identify differences in gene expression.
- the markers are used to select, in back-cross populations, the plant that have the higher percentage of recurrent parent, while still remaining the genes given by the donor plant .
- the invention further provides variant forms of nucleic acids and corresponding proteins.
- the nucleic acids comprise at least 10 contiguous amino acids of one of the sequences for example as described in Table I, in any of the allelic forms shown. Some nucleic acid encode full-length proteins .
- Genes can be expressed in an expression vector in which a gene is operably linked to a native or other promoter.
- the promoter is an eukaryotic promoter for expression in a eukaryotic cell.
- the transcription regulation sequences typically include an heterologous promoter and U optionally an enhancer which is recognized by the host.
- the selection of an appropriate promoter for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA promoters, depends on the host selected.
- Commercially available expression vectors can be used.
- Vectors can include host-recognized replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.
- the means of introducing the expression construct into a host cell varies depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection, as described in Sambrook, supra .
- a wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as E . coli , yeast, filamentous fungi, insect cells, mammalian cells, typically immortalized, e.g., mouse, CHO, human and monkey cell lines and derivatives thereof, and plant cells. Preferred host cells are able to process the variant gene product to produce an appropriate mature polypeptide . Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like .
- the DNA fragments are introduced into cultured plant cells by standard methods including electroporation
- the Ti plasmid is transmitted to plant cells upon infection by Agrobacterium tumefaciens, and is stably integrated into the plant genome (Horsch et al . , Science, 233, 496-498 (1984); Fraley et al . , Proc . Natl . Acad. Sci . USA 80, 4803 (1983)).
- the protein may be isolated by conventional means of protein biochemistry and purification to obtain a substantially pure product, i.e., 80, 95 or 99% free of cell component contaminants, as described in Jacoby, Methods in Enzymol ogy Volume 104, Academic Press, New York (1984); Sc:ope ⁇ , Protein Purification, Principles and Practice ' , 2nd Edition, Springer-Verlag, New York (1987); and Deutscher (ed) , Guide to Protein Purification ' Me thods in Enzymology, Vol. 182 (1990). If the protein is secreted, it can be isolated from the supernatant in which the host cell is grown. If not secreted, the protein can be isolated from a lysate of the host cells.
- the invention further provides transgenic plants capable of expressing an exogenous variant gene and/or having one or both alleles of an endogenous variant gene inactivated. Plant regeneration from cultural protoplasts is described in Evans et al . , "Protoplasts Isolation and Culture," Handbook of Plant Cell Cul tures 1 , 124-176 (MacMillan Publishing Co., New York, 1983); Davey, “Recent Developments in the Culture and Regeneration of Plant Protoplasts," Protoplasts, (1983) - pp. 12-29, (Birkhauser, Basal 1983); Dale, "Protoplast Culture and Plant Regeneration of Cereals and Other Recalcitrant Crops," Protoplasts (1983) - pp.
- a variant gene responsible for a disease-resistant phenotype can be introduced into the plant to simulate that phenotype.
- Expression of an exogenous variant gene is usually achieved by operably linking the qene to a promoter and optionally an enhancer.
- Inactivation of an exogenous variant genes can be achieved by forming a transgene in which a cloned variant genes is inactivated by insertion of a positive selection marker. See Capecchi, Science 244, 1288-1292 (1989) .
- transgenic plant are useful in a variety of screening assays.
- the transgenic plant can then be treated with compounds of interest and the effect of those compounds on the disease resistance can be monitored.
- the transgenic plant can be exposed to a variety of environmental conditions to determine the effect of those conditions on the resistance to the disease.
- the present invention includes biologically active fragments of the polypeptides, or analogs thereof, including organic molecules which simulate the interactions of the peptides .
- biologically active fragments include any portion of the full-length polypeptide which confers a biological function on the variant gene product, including ligand binding, and antibody binding.
- Ligand binding includes binding by nucleic acids, proteins or polypeptides, small biologically active molecules, or large cellular structures.
- Antibodies that specifically bind to one allelic gene products but not to a second allelic gene product are also provided.
- Antibodies can be made by injecting mice or other animals with the variant gene product or synthetic peptide fragments thereof. Monoclonal antibodies are screened as are described, for example, in Harlow & Lane, Antibodies, A Laboratory Manual , Cold Spring Harbor Press, New York (1988) ; Goding, Monoclonal antibodies, Principles and Practice (2d ed. ) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product. These antibodies are useful in diagnostic assays for detection of the variant form, or as an active ingredient in a pharmaceutical composition.
- kits comprising at least one allele-specific oligonucleotide as described above. Often, the kits contain one or more pairs of 2? allele-specific oligonucleotides hybridizing to different forms of a polymorphism. In some kits, the allele-specific oligonucleotides are provided immobilized to a substrate. For example, the same substrate can comprise allele-specific oligonucleotide probes for detecting at least 10, 100 or all of the polymorphisms shown in Table I.
- kits include, for example, restriction enzymes, reverse-transcriptase or polymerase, the substrate nucleoside triphosphates , means used to label ( or example, an avidin-enzyme conjugate and enzyme substrate and chromogen if the label is biotin) , and the appropriate-buffers for reverse transcription, PCR, or hybridization reactions.
- the kit also contains instructions for carrying out the methods .
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97955036A EP0944741A2 (en) | 1996-12-02 | 1997-12-02 | Vegetal sequences including a polymorphic site and their uses |
AU72066/98A AU7206698A (en) | 1996-12-02 | 1997-12-02 | Vegetal sequences including a polymorphic site and their uses |
CA002274317A CA2274317A1 (en) | 1996-12-02 | 1997-12-02 | Vegetal sequences including a polymorphic site and their uses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3206996P | 1996-12-02 | 1996-12-02 | |
US60/032,069 | 1996-12-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998030717A2 true WO1998030717A2 (en) | 1998-07-16 |
WO1998030717A3 WO1998030717A3 (en) | 1999-04-29 |
Family
ID=21862927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/007134 WO1998030717A2 (en) | 1996-12-02 | 1997-12-02 | Vegetal sequences including a polymorphic site and their uses |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0944741A2 (en) |
AU (1) | AU7206698A (en) |
CA (1) | CA2274317A1 (en) |
WO (1) | WO1998030717A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030717A3 (en) * | 1996-12-02 | 1999-04-29 | Biocem S A | Vegetal sequences including a polymorphic site and their uses |
WO2000029623A3 (en) * | 1998-11-17 | 2001-04-19 | Curagen Corp | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
WO2001051670A3 (en) * | 2000-01-07 | 2002-02-28 | Curagen Corp | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
WO2001038586A3 (en) * | 1999-11-24 | 2002-04-25 | Richard A Shimkets | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
WO2001040521A3 (en) * | 1999-11-30 | 2002-05-16 | Curagen Corp | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
WO2001048245A3 (en) * | 1999-12-27 | 2002-11-28 | Curagen Corp | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
EP1119644A4 (en) * | 1998-10-06 | 2003-06-25 | Univ Emory | MOLECULAR DIAGNOSIS OF GALACTOSEMIA |
EP2147012A2 (en) * | 2007-05-17 | 2010-01-27 | Monsanto Technology, LLC | Corn polymorphisms and methods of genotyping |
WO2011151405A1 (en) | 2010-06-04 | 2011-12-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2634208B2 (en) * | 1987-11-13 | 1997-07-23 | パイオニア・ハイ―ブレツド・インターナシヨナル・インコーポレイテツド | Method and apparatus for analyzing restriction fragment length polymorphism |
EP0402401A4 (en) * | 1988-02-22 | 1991-09-11 | Pioneer Hi-Bred International | Genetic linkages between agronomically important genes and restriction fragment length polymorphisms |
AU8953991A (en) * | 1990-11-06 | 1992-05-26 | Lubrizol Corporation, The | Compositions and methods for analyzing genomic variation |
US5437697A (en) * | 1992-07-07 | 1995-08-01 | E. I. Du Pont De Nemours And Company | Method to identify genetic markers that are linked to agronomically important genes |
US5332408A (en) * | 1992-08-13 | 1994-07-26 | Lakeside Biotechnology, Inc. | Methods and reagents for backcross breeding of plants |
DK0785281T3 (en) * | 1995-07-28 | 2004-09-06 | Sapporo Breweries | Method for genetic differentiation of hop species |
US6114116A (en) * | 1996-12-02 | 2000-09-05 | Lemieux; Bertrand | Brassica polymorphisms |
AU7206698A (en) * | 1996-12-02 | 1998-08-03 | Biocem S.A. | Vegetal sequences including a polymorphic site and their uses |
AU6024598A (en) * | 1997-01-10 | 1998-08-03 | Pioneer Hi-Bred International, Inc. | Hybridization-based genetic amplification and analysis |
-
1997
- 1997-12-02 AU AU72066/98A patent/AU7206698A/en not_active Abandoned
- 1997-12-02 EP EP97955036A patent/EP0944741A2/en not_active Withdrawn
- 1997-12-02 WO PCT/EP1997/007134 patent/WO1998030717A2/en not_active Application Discontinuation
- 1997-12-02 CA CA002274317A patent/CA2274317A1/en not_active Abandoned
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030717A3 (en) * | 1996-12-02 | 1999-04-29 | Biocem S A | Vegetal sequences including a polymorphic site and their uses |
EP1119644A4 (en) * | 1998-10-06 | 2003-06-25 | Univ Emory | MOLECULAR DIAGNOSIS OF GALACTOSEMIA |
WO2000029623A3 (en) * | 1998-11-17 | 2001-04-19 | Curagen Corp | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
US6670464B1 (en) | 1998-11-17 | 2003-12-30 | Curagen Corporation | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
WO2001038586A3 (en) * | 1999-11-24 | 2002-04-25 | Richard A Shimkets | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
WO2001040521A3 (en) * | 1999-11-30 | 2002-05-16 | Curagen Corp | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
WO2001048245A3 (en) * | 1999-12-27 | 2002-11-28 | Curagen Corp | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
WO2001051670A3 (en) * | 2000-01-07 | 2002-02-28 | Curagen Corp | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
EP2147012A2 (en) * | 2007-05-17 | 2010-01-27 | Monsanto Technology, LLC | Corn polymorphisms and methods of genotyping |
EP2147012A4 (en) * | 2007-05-17 | 2011-03-02 | Monsanto Technology Llc | Corn polymorphisms and methods of genotyping |
WO2011151405A1 (en) | 2010-06-04 | 2011-12-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence |
Also Published As
Publication number | Publication date |
---|---|
AU7206698A (en) | 1998-08-03 |
WO1998030717A3 (en) | 1999-04-29 |
EP0944741A2 (en) | 1999-09-29 |
CA2274317A1 (en) | 1998-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5856104A (en) | Polymorphisms in the glucose-6 phosphate dehydrogenase locus | |
JP5281392B2 (en) | Elite event A5547-127 and methods and kits for identifying the event in biological samples | |
AU2001235414B2 (en) | Methods and kits for identifying elite event gat-zm1 in biological samples | |
Burow et al. | Molecular tools for the study of complex traits | |
US6733965B2 (en) | Microsatellite DNA markers and uses thereof | |
WO1998020165A2 (en) | Biallelic markers | |
AU2001235414A1 (en) | Methods and kits for identifying elite event GAT-ZM1 in biological samples | |
EP2342337B1 (en) | Method for diagnostic marker development | |
AU637768B2 (en) | Genetic identification employing dna probes of variable number tandem repeat loci | |
US6114116A (en) | Brassica polymorphisms | |
WO1998038846A2 (en) | Genetic compositions and methods | |
KR102198566B1 (en) | Tetra primers ARMS-PCR molecular marker for discriminating cultivars of sweet potato and uses thereof | |
KR20180077871A (en) | SNP markers for discrimination of Jubilee type or Crimson type watermelon cultivar | |
US6358686B1 (en) | Brassica polymorphisms | |
US20020032319A1 (en) | Human single nucleotide polymorphisms | |
WO1998030717A2 (en) | Vegetal sequences including a polymorphic site and their uses | |
EP0812922A2 (en) | Polymorphisms in human mitochondrial nucleic acid | |
CA2324285A1 (en) | Coding sequence polymorphisms in vascular pathology genes | |
CA2294037A1 (en) | Method of determining the genotype of an organism using an allele specific oligonucleotide probe which hybridises to microsatellite flanking sequences | |
KR20220086087A (en) | Snp marker set for identifying cucurbita maxima cultivars and method for identifying cucurbita maxima cultivars using the same | |
KR101748366B1 (en) | Molecular marker for selecting tomato leaf mold resistant and selection method using the same molecular marker | |
WO1998058529A2 (en) | Genetic compositions and methods | |
KR102458440B1 (en) | Primer set for selecting Phytophthora blight resistant pepper and selection method using the same primer set | |
US6500616B1 (en) | Methods of monitoring genomic integrity and detecting genomic destabilization of plant cells in tissue culture | |
US20030039973A1 (en) | Human single nucleotide polymorphisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2274317 Country of ref document: CA Ref country code: CA Ref document number: 2274317 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997955036 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997955036 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09319401 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997955036 Country of ref document: EP |